RESPIRERX PHARMACEUTICALS INC.: 10-Q filed 2014-12-15
What RESPIRERX PHARMACEUTICALS INC. reported in its quarterly report filed 2014-12-15 (fiscal Q2 2013): 21 published measures, 54 facts as tagged in accession 0001493152-14-004143.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-12-15
- Fiscal period
- fiscal Q2 2013
- Accession
- 0001493152-14-004143 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All RESPIRERX PHARMACEUTICALS INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-06-30 | 53,988 | USD | |
| At 2012-12-31 | 198,726 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-06-30 | -4,008,852 | USD | |
| At 2012-12-31 | -2,991,695 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-06-30 | 25,570 | USD | |
| At 2012-12-31 | 152,179 | USD | |
| At 2012-06-30 | 532,876 | USD | |
| At 2011-12-31 | 1,610,945 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-04-01 to 2013-06-30 | -179,771 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -1,017,157 | USD | 181 |
| 2012-01-01 to 2012-12-31 | -7,572,244 | USD | 366 |
| 2012-04-01 to 2012-06-30 | -995,007 | USD | 91 |
| 2012-01-01 to 2012-06-30 | -1,928,777 | USD | 182 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-06-30 | -138,281 | USD | 181 |
| 2012-01-01 to 2012-12-31 | -1,861,870 | USD | 366 |
| 2012-01-01 to 2012-06-30 | -1,457,965 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-06-30 | 11,672 | USD | 181 |
| 2012-01-01 to 2012-06-30 | 378,404 | USD | 182 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-06-30 | 1,492 | USD | 182 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-06-30 | -129,358,488 | USD | |
| At 2012-12-31 | -128,341,331 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-06-30 | 34,641 | USD | 182 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-04-01 to 2013-06-30 | -177,232 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -1,020,449 | USD | 181 |
| 2012-04-01 to 2012-06-30 | -972,031 | USD | 91 |
| 2012-01-01 to 2012-06-30 | -1,906,385 | USD | 182 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-06-30 | 53,988 | USD | |
| At 2012-12-31 | 169,181 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-04-01 to 2013-06-30 | 14,680 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 29,717 | USD | 181 |
| 2012-04-01 to 2012-06-30 | 7,885 | USD | 91 |
| 2012-01-01 to 2012-06-30 | 8,890 | USD | 182 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-06-30 | 4,062,840 | USD | |
| At 2012-12-31 | 3,190,421 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-04-01 to 2013-06-30 | 177,232 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 1,020,449 | USD | 181 |
| 2012-04-01 to 2012-06-30 | 1,020,340 | USD | 91 |
| 2012-01-01 to 2012-06-30 | 1,954,694 | USD | 182 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-04-01 to 2013-06-30 | 74,993 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 158,671 | USD | 181 |
| 2012-04-01 to 2012-06-30 | 264,295 | USD | 91 |
| 2012-01-01 to 2012-06-30 | 467,276 | USD | 182 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-06-30 | 144,041,556 | shares | |
| At 2012-12-31 | 144,041,556 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-06-30 | 125,183,892 | USD | |
| At 2012-12-31 | 125,183,892 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-12-31 | 29,545 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-06-30 | 0 | USD | 181 |
| 2012-01-01 to 2012-06-30 | 0 | USD | 182 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-04-01 to 2013-06-30 | 104,229 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 863,768 | USD | 181 |
| 2012-04-01 to 2012-06-30 | 594,798 | USD | 91 |
| 2012-01-01 to 2012-06-30 | 1,326,171 | USD | 182 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-06-30 | 13,843 | USD | 182 |
Inspect the source
- Entity
- RESPIRERX PHARMACEUTICALS INC. / CIK 0000849636
- Captured
- SEC response SHA-256
f692532c7d166963e2fad68da28689f5b935e4c0402c22ccfa62bc8615c926ab
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000849636.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))